JAK2 and myeloproliferative disorder: Potential candidates for Y are revealed by the structure of our proposed model, allowing it to describe gene expression levels measured to date as long as five interactions/regulatory dependences are satisfied: (i)In MPN, the expression of PRMT5 is higher in cells with the JAK2 V617F mutation (Pastore et al.